Cover Image
市場調查報告書

再生不良性貧血:開發中產品分析

Aplastic Anemia - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 245971
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
Back to Top
再生不良性貧血:開發中產品分析 Aplastic Anemia - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 79 Pages
簡介

再生不良性貧血是具有末梢性全血球減少症及骨髓形成不全等特徵的骨髓損傷症。症狀有疲勞,膚色青白,心律急速或不規則,運動性喘不過氣,鼻血,齒齦出血,長刀傷造成的出血,皮疹,暈眩,頭痛等。危險因素有暴露在有毒的化學物質,癌症的高輻射劑量放射治療或化療,特定的血液疾病,自體免疫不全,嚴重的感染疾病等。治療有使用免疫抑製藥與幹細胞移植等。

本報告提供全球各國治療再生不良性貧血所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查結果。

簡介

  • 分析範圍

再生不良性貧血概要

治療藥的開發

  • 再生不良性貧血開發中產品:概要

各企業開發中的再生不良性貧血治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

再生不良性貧血治療藥:開發中的產品一覽(各企業)

再生不良性貧血開發治療藥的企業

  • 3SBio Inc.
  • Acceleron Pharma, Inc.
  • Amgen Inc.
  • BioLineRx, Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pluristem Therapeutics Inc.
  • Regen BioPharma, Inc.

再生不良性貧血:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

再生不良性貧血治療藥:最新的開發平台趨勢

再生不良性貧血治療藥:暫停的計劃

再生不良性貧血治療藥:中止開發的產品

再生不良性貧血相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9321IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Pipeline Review, H1 2017, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.

Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 2, 1, 1 and 5 respectively.

Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Aplastic Anemia - Overview
    • Aplastic Anemia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Aplastic Anemia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Aplastic Anemia - Companies Involved in Therapeutics Development
    • 3SBio Inc
    • Acceleron Pharma Inc
    • Amgen Inc
    • BioLineRx Ltd
    • F. Hoffmann-La Roche Ltd
    • Gamida Cell Ltd
    • Novartis AG
    • Pluristem Therapeutics Inc
    • Regen BioPharma Inc
  • Aplastic Anemia - Drug Profiles
    • Anemir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BL-8040 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Aplastic Anemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CordIn - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eltrombopag olamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HemaXellerate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLXR-18 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • romiplostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sotatercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • thrombopoietin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Aplastic Anemia - Dormant Projects
  • Aplastic Anemia - Discontinued Products
  • Aplastic Anemia - Product Development Milestones
    • Featured News & Press Releases
      • Apr 20, 2017: NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia
      • Oct 24, 2016: Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, for treatment of Bone Marrow Suppression Study
      • Sep 22, 2016: Regen BioPharma Responds to FDA Comments on Its Application for Orphan Drug Designation on its Aplastic Anemia Therapy
      • Aug 25, 2016: Health Canada issues advisory on REVOLADE citing risk of severe hepatotoxicity
      • May 11, 2016: Regen BioPharma Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
      • May 03, 2016: Regen BioPharma Receives Preliminary Clinical Data from Pan Am Cancer Center Regarding Their HemaXellerate Study in Cancer Patients
      • Jan 26, 2016: Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product
      • Dec 15, 2015: Regen BioPharma Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate
      • Nov 23, 2015: BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions
      • Nov 17, 2015: Regen BioPharma Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application
      • Nov 17, 2015: Pluristem to Present New Data on PLX-R18 at American Society of Hematology's Annual Meeting
      • Sep 25, 2015: Regen BioPharma Announces Positive Results from GLP Safety Study for HemaXellerate
      • Sep 10, 2015: BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia
      • Sep 02, 2015: Novartis receives EU approval for new Revolade use as first-in-class therapy for patients with severe aplastic anemia
      • Jul 24, 2015: Novartis drug Revolade recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Aplastic Anemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Aplastic Anemia - Pipeline by 3SBio Inc, H1 2017
  • Aplastic Anemia - Pipeline by Acceleron Pharma Inc, H1 2017
  • Aplastic Anemia - Pipeline by Amgen Inc, H1 2017
  • Aplastic Anemia - Pipeline by BioLineRx Ltd, H1 2017
  • Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Aplastic Anemia - Pipeline by Gamida Cell Ltd, H1 2017
  • Aplastic Anemia - Pipeline by Novartis AG, H1 2017
  • Aplastic Anemia - Pipeline by Pluristem Therapeutics Inc, H1 2017
  • Aplastic Anemia - Pipeline by Regen BioPharma Inc, H1 2017
  • Aplastic Anemia - Dormant Projects, H1 2017
  • Aplastic Anemia - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Aplastic Anemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top